Premium
Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma
Author(s) -
Sveijer Malin,
Bahr Greenwood Tatiana,
Jädersten Martin,
Kvedaraite Egle,
Zetterberg Henrik,
Blennow Kaj,
Lourda Magda,
Gavhed Désirée,
Henter JanInge
Publication year - 2022
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18247
Subject(s) - neurodegeneration , langerhans cell histiocytosis , cerebrospinal fluid , pathology , biomarker , medicine , neurofilament , histiocytosis , central nervous system , biology , disease , immunohistochemistry , biochemistry
Summary Patients with Langerhans cell histiocytosis (LCH) may develop progressive neurodegeneration in the central nervous system (ND‐CNS‐LCH). Neurofilament light protein (NFL) in cerebrospinal fluid (CSF) is a promising biomarker to detect and monitor ND‐CNS‐LCH. We compared paired samples of NFL in plasma (p‐NFL) and CSF in 10 patients (19 samples). Nine samples had abnormal CSF‐NFL (defined as ≥380 ng/l) with corresponding p‐NFL ≥ 2 ng/l. Ten samples had CSF‐NFL < 380 ng/l; eight (80%) with p‐NFL < 2 ng/l ( p < 0.001; Fisher's exact test). Thus, our results suggest that p‐NFL may be used to screen for ND‐CNS‐LCH. Further studies are encouraged, including the role of p‐NFL for monitoring of ND‐CNS‐LCH.